Bill Maughan Stock Analyst Profile - Canaccord Genuity Research Coverage - Stocknear

Bill Maughan

Stock Analyst at Canaccord Genuity

(3.23)
# 2846
Out of 5,477 analysts
17
Total ratings
Success rate
Average return
Main Sectors:
Top Industries:
10 Stocks
Name Action PT Current % Upside Ratings Updated
YMAB Y-mAbs Therapeutics
Downgrades: Hold
26 9
8.59 0.12% 3 Aug 6, 2025
KRYS Krystal Biotech
Initiates Coverage On: Buy
190
144.36 31.62% 1 Jul 1, 2025
CRSP CRISPR Therapeutics
Downgrades: Hold
45
55.89 -19.48% 1 Jun 27, 2025
NKTX Nkarta
Maintains: Buy
16 15
2.07 624.64% 2 May 10, 2024
FATE Fate Therapeutics
Maintains: Buy
11 9
1.02 782.35% 1 May 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
63 67
36.57 83.21% 3 May 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
91 106
25.39 317.49% 3 May 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
22 24
0.52 4515.38% 1 Mar 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
60
7.02 754.7% 1 Feb 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
45
69.8 -35.53% 1 Nov 2, 2023